SUBCUTANEOUS SARILUMAB FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH MODERATE TO SEVERE COVID19 DISEASE: A PRAGMATIC, EMBEDDED RANDOMIZED CLINICAL TRIAL.

Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial.

Importance and objectiveThe aim of this pragmatic, embedded, adaptive trial was to measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added to an evolving standard of care (SOC), for clinical management of inpatients with moderate to severe COVID-19 disease.DesignTwo-arm, randomized, open-label controlled trial compar

read more